VectivBio Holding AG VECT
Set alert
16.87 +16.87 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 1.06B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -8.69
- Beta
- 0.10
- Short ratio
- 0.04
- Inst. own
- 83.80%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 19, 2023
- 50-d avg
- 15.03
- 200-d avg
- 9.90
- 1y target
- 18.33
2Y chart
Events in this range
- Jul 7, 2022Earnings: —; estimate -0.64; surprise —%
- Apr 6, 2023Earnings: —; estimate -0.48; surprise —%
Signals (76)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Jun 9, 2023 | 3 years ago |
| MACD: Buy Signal | May 22, 2023 | 3 years ago |
| RSI: Overbought | May 22, 2023 | 3 years ago |
| MACD: Sell Signal | May 17, 2023 | 3 years ago |
| RSI: Overbought | May 11, 2023 | 3 years ago |
| MACD: Buy Signal | May 10, 2023 | 3 years ago |
| MACD: Sell Signal | May 8, 2023 | 3 years ago |
| RSI: Overbought | Apr 21, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 19, 2023 | 3 years ago |
| SMA: Bullish | Apr 18, 2023 | 3 years ago |
| SMA: Bearish | Apr 17, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 17, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 28, 2023 | 3 years ago |
| SMA: Bullish | Mar 24, 2023 | 3 years ago |
| SMA: Bearish | Mar 10, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 8, 2023 | 3 years ago |
| SMA: Bearish | Mar 7, 2023 | 3 years ago |
| SMA: Bullish | Feb 17, 2023 | 3 years ago |
| MACD: Buy Signal | Feb 17, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 16, 2023 | 3 years ago |
| SMA: Bearish | Feb 9, 2023 | 3 years ago |
| SMA: Bullish | Feb 8, 2023 | 3 years ago |
| SMA: Bearish | Feb 7, 2023 | 3 years ago |
| SMA: Bullish | Feb 2, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 31, 2023 | 3 years ago |
| SMA: Bearish | Jan 11, 2023 | 3 years ago |
| MACD: Sell Signal | Dec 30, 2022 | 3 years ago |
| MACD: Buy Signal | Dec 14, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 10, 2022 | 3 years ago |
| RSI: Overbought | Nov 8, 2022 | 3 years ago |
| RSI: Overbought | Nov 4, 2022 | 3 years ago |
| RSI: Overbought | Oct 28, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 26, 2022 | 4 years ago |
| MACD: Sell Signal | Oct 25, 2022 | 4 years ago |
| RSI: Overbought | Oct 13, 2022 | 4 years ago |
| RSI: Overbought | Oct 3, 2022 | 4 years ago |
| SMA: Bullish | Sep 30, 2022 | 4 years ago |
| SMA: Bullish | Sep 30, 2022 | 4 years ago |
| MACD: Buy Signal | Sep 26, 2022 | 4 years ago |
| SMA: Bearish | Sep 9, 2022 | 4 years ago |
| SMA: Bullish | Sep 7, 2022 | 4 years ago |
| SMA: Bullish | Aug 31, 2022 | 4 years ago |
| SMA: Bearish | Aug 30, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 17, 2022 | 4 years ago |
| SMA: Bearish | Aug 16, 2022 | 4 years ago |
| SMA: Bullish | Aug 15, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 15, 2022 | 4 years ago |
| SMA: Bearish | Aug 2, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Jul 29, 2022 | 4 years ago |
| SMA: Bullish | Jul 28, 2022 | 4 years ago |
| SMA: Bearish | Jul 22, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 22, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 5, 2022 | 4 years ago |
| SMA: Bullish | Jul 1, 2022 | 4 years ago |
| SMA: Bearish | Jun 30, 2022 | 4 years ago |
| SMA: Bullish | Jun 17, 2022 | 4 years ago |
| SMA: Bearish | Jun 15, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 8, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 7, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 1, 2022 | 4 years ago |
| RSI: Overbought | May 20, 2022 | 4 years ago |
| SMA: Bullish | May 12, 2022 | 4 years ago |
| MACD: Buy Signal | May 6, 2022 | 4 years ago |
| RSI: Oversold | Apr 28, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 26, 2022 | 4 years ago |
| SMA: Bearish | Apr 19, 2022 | 4 years ago |
| SMA: Bullish | Apr 14, 2022 | 4 years ago |
| MACD: Buy Signal | Apr 12, 2022 | 4 years ago |
| SMA: Bearish | Mar 23, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 2, 2022 | 4 years ago |
| MACD: Buy Signal | Feb 9, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 21, 2022 | 4 years ago |
| MACD: Buy Signal | Jan 20, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 19, 2022 | 4 years ago |
| RSI: Oversold | Dec 1, 2021 | 4 years ago |
Key statistics
- Market cap
- 1.06B
- Enterprise value
- 846.20M
- Trailing P/E
- 0.00
- Forward P/E
- -8.69
- PEG ratio
- 0.00
- Price / sales
- 38.71
- Price / book
- 4.95
- EPS (TTM)
- -2.10
- Beta
- 0.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 27.34M
- Revenue growth
- 0.00%
- Free cash flow
- -23.45M
- Total cash
- 221.42M
- Total debt
- 10.46M
- Return on equity
- -56.92%
- Shares outstanding
- 62.81M
- Short % of float
- 0.15%
- 50-day average
- 15.03
- 200-day average
- 9.90
Analyst view
Consensus: hold
Hold
Price target (mean) 18.33 +8.7% upside
Now 16.87
- Target (low)
- 17.00
- Target (mean)
- 18.33
- Target (high)
- 21.00
Next earnings
Jul 19, 2023
Expected Jul 19, 2023. Consensus EPS estimate 0.00.
Financials — quick view
VECT Revenue — annual 27.34M
VECT Net income — annual -93.73M
VECT EPS — annual -2.12
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 19, 2023 | Mar 1, 2023 | -0.43 | — | — | — |
| Apr 6, 2023 | Dec 1, 2022 | -0.48 | — | — | — |
| Jul 7, 2022 | Mar 1, 2022 | -0.64 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 4, 2021 | Credit Suisse | init | — | Outperform |
| May 4, 2021 | B of A Securities | init | — | Buy |
| May 4, 2021 | SVB Leerink | init | — | Outperform |
About VectivBio Holding AG
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- vectivbio.com
News
- Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
- Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
- Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround
- VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT
- VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT
- Why Shares of VectivBio Holding Are Up Today
- VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion
- VECT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of VectivBio Holding AG Is Fair to Shareholders
- Ironwood Pharmaceuticals to Acquire VectivBio for About $1 Billion
- Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion
Your note
Sign in to keep a note on VECT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| CHI Advisors LLC | 8.38% | 5,255,484 | 88.55M | Mar 30, 2023 |
| Orbimed Advisors LLC. | 8.22% | 5,156,561 | 86.89M | Mar 30, 2023 |
| Citadel Advisors Llc | 6.32% | 3,967,537 | 66.85M | Mar 30, 2023 |
| Eventide Asset Management LLC | 5.86% | 3,675,644 | 61.93M | Mar 30, 2023 |
| Novo Holdings A/S | 5.75% | 3,610,461 | 60.84M | Mar 30, 2023 |
| Tcg Crossover Management, Llc | 4.96% | 3,113,600 | 52.46M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | 5.43% | 3,405,644 | 57.39M | Dec 30, 2022 |
| Tekla Healthcare Investors | 0.88% | 553,446 | 9.33M | Dec 30, 2022 |
| Tekla Life Sciences Investors | 0.29% | 184,258 | 3.10M | Dec 30, 2022 |
| Brinker Capital Destinations Tr-Destinations Small-Mid Cap Equity Fd | 0.12% | 74,031 | 1.25M | Feb 27, 2023 |
| Driehaus Micro Cap Growth Fund | 0.07% | 43,339 | 730.26K | Dec 30, 2022 |
| RBB Fund Inc.-Adara Smaller Companies Fund | 0.04% | 27,715 | 467.00K | Mar 30, 2023 |